Compare FCN & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCN | RLAY |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.1B |
| IPO Year | 1996 | 2020 |
| Metric | FCN | RLAY |
|---|---|---|
| Price | $154.95 | $20.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $165.00 | $19.50 |
| AVG Volume (30 Days) | 520.2K | ★ 4.1M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.51 | ★ 31.78 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $3,788,857,000.00 | $15,355,000.00 |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $7.10 | $324.03 |
| P/E Ratio | $82.22 | ★ N/A |
| Revenue Growth | 2.44 | ★ 53.44 |
| 52 Week Low | $137.65 | $3.03 |
| 52 Week High | $189.30 | $20.20 |
| Indicator | FCN | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 72.20 |
| Support Level | $150.66 | $12.10 |
| Resistance Level | $166.46 | N/A |
| Average True Range (ATR) | 5.52 | 1.24 |
| MACD | 1.45 | 0.21 |
| Stochastic Oscillator | 74.65 | 98.78 |
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.